Table 3.
Risk Estimates for STK15 Phe31Ile and Val57Ile Haplotypes in Esophageal Cancer Patients Treated by Preoperative CTXRT
| Haplotype | Clinical | Outcome | Adjusted OR* (95% CI) |
|---|---|---|---|
| STK31- STK57 | <path CR | path CR | |
| wild-wild | 37 | 28 | Reference |
| variant-wild | 55 | 20 | 2.53 1.15-5.54 |
| wild-variant | 20 | 9 | 2.21 0.73-6.15 |
| variant-variant | 12 | 7 | 0.91 0.26-3.17 |
| STK31- STK57 | Recurrence | No recurrence | |
| wild-wild | 13 | 524 | Reference |
| variant-wild | 29 | 46 | 4.39 (2.16-8.94) |
| wild-variant | 7 | 22 | 0.66 0.16-2.76 |
| variant-variant | 10 | 9 | 2.93 0.68-12.68 |
| STK31- STK57 | Dead | Not dead | |
| wild-wild | 27 | 38 | Reference |
| variant-wild | 43 | 32 | 1.65 0.69-3.92 |
| wild-variant | 14 | 15 | 1.27 0.35-4.56 |
| variant-variant | 11 | 8 | 3.79 0.74-19.35 |
| STK31- STK57 | Dead or recurrence |
Not dead or recurrence |
|
| wild-wild | 29 | 36 | Reference |
| variant-wild | 45 | 30 | 1.64 0.69-3.89 |
| wild-variant | 14 | 15 | 0.85 0.25-2.91 |
| variant-variant | 13 | 6 | 3.28 0.75-14.36 |
Abbreviations: CI, confidence interval; CTXRT, chemoradiotherapy; OR, odds ratio; SNP, single nucleotide polymorphism.
a
Adjusted by age, gender, tumor type, tumor location, histology, clinical stage, radiation dose, chemoradiation sequence, and chemotherapy regimens.